This filing discloses that multiple analysts have adjusted their price targets for Pfizer following its Q3 2026 earnings release. The adjustments show mixed sentiment, with one firm lowering its target and two raising theirs, reflecting varied interpretations of the company's recent performance and outlook.
Following Pfizer's third-quarter 2026 financial results, analysts from Morgan Stanley, RBC, and UBS updated their price targets. Morgan Stanley lowered its target, indicating a more cautious outlook, while RBC and UBS raised theirs, suggesting a more optimistic view on Pfizer's growth trajectory, cost-cutting measures, and product performance. This mixed sentiment reflects the ongoing debate among investors about Pfizer's future prospects. For traders, the short-term implication is increased volatility as the market digests these differing analyst opinions. Long-term, the varying targets highlight the uncertainty surrounding Pfizer's ability to execute its strategy and maintain growth, presenting both a risk for downside if the more conservative views prevail and an opportunity if the optimistic targets are met.